{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:51:23Z","timestamp":1760028683118},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1097\/coc.0b013e31827ecd1d","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T18:30:15Z","timestamp":1361471415000},"page":"545-549","source":"Crossref","is-referenced-by-count":9,"title":["Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer"],"prefix":"10.1097","volume":"37","author":[{"given":"Emilio","family":"Bajetta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Buzzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erminia","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Valvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia F.","family":"Dotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Biondani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpine","family":"Gevorgyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210128","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1056\/NEJM200108303450910","article-title":"Refining multimodal therapy for rectal cancer.","volume":"345","author":"Nelson","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-5-20210128","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJM199408253310803","article-title":". Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.","volume":"331","author":"OConnell","year":"1994","journal-title":"N Engl J Med"},{"key":"R3-5-20210128","first-page":"21","article-title":"The experimental and clinical rationale for the use of S-phase-aspecific radiosensitizer to overcome tumor cell population.","volume":"19","author":"McGinn","year":"1992","journal-title":"Sem Oncol"},{"key":"R4-5-20210128","first-page":"184","article-title":"An approach to the radiosensitization of human tumors.","volume":"2","author":"Kinsella","year":"1996","journal-title":"Cancer J"},{"key":"R5-5-20210128","first-page":"3203","article-title":"Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation.","volume":"56","author":"Lawrence","year":"1996","journal-title":"Cancer Res"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine.","volume":"40","author":"Reigner","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer (X-ACT trial).","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":". Comparison of oral capecitabine versus intravenous fluoouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":". Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.","volume":"25","author":"Haller","year":"2011","journal-title":"J Clin Oncol"},{"key":"R10-5-20210128","first-page":"2948","article-title":". X-ray irradiation induces thymidine phosphorilase and enhance the efficacy of capecitabine in human cancer xenograft.","volume":"5","author":"Sawada","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1179\/joc.2006.18.1.85","article-title":". Capecitabine chemoradiation for rectal cancer after curative surgery.","volume":"18","author":"Bajetta","year":"2006","journal-title":"J Chemotherapy"},{"key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","article-title":". Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.","volume":"13","author":"Hofheinz","year":"2012","journal-title":"Lancet Oncol"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","article-title":". Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 120405-Prodige 2.","volume":"28","author":"Gerard","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.surg.2009.05.005","article-title":". Circadian variation in intestinal dihydropyrimidine-dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chrono-chemotherapy.","volume":"146","author":"Abolmaali","year":"2009","journal-title":"Surgery"},{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1535-7163.MCT-06-0177","article-title":"Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index.","volume":"5","author":"Wood","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"R16-5-20210128","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/jnci\/88.17.1193","article-title":"Radiosensitizing nucleosides.","volume":"88","author":"McGinn","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1146\/annurev.pharmtox.47.120505.105208","article-title":"Circardian rhythms: mechanism and therapeutic implications.","volume":"47","author":"Levi","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<217::AID-CNCR5>3.0.CO;2-I","article-title":". Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuos chronobiolocically shaped 5-fluorouracil infusion and radiation therapy.","volume":"78","author":"Marsh","year":"1996","journal-title":"Cancer"},{"key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdn002","article-title":". Chronomodulate capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-fluorouracil.","volume":"19","author":"Qvortrup","year":"2008","journal-title":"Ann Oncol"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":". Preoperative versus postoperative chemoradiotherapy for rectal cancer.","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1200\/JCO.2002.02.049","article-title":". Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.","volume":"20","author":"Dunst","year":"2002","journal-title":"J Clin Oncol"},{"key":"R22-5-20210128","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0360-3016(03)00275-X","article-title":". Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.","volume":"56","author":"Souglakos","year":"2003","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"R23-5-20210128","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00280-006-0302-x","article-title":". Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.","volume":"59","author":"Santini","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1200\/JCO.1997.15.5.2030","article-title":". Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of Intergroup 0114.","volume":"15","author":"Tepper","year":"1997","journal-title":"J Clin Oncol"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0360-3016(98)00084-4","article-title":". Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma.","volume":"41","author":"Miller","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R27-5-20210128","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Lim do H, Kim S, et al.. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"key":"R28-5-20210128","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1200\/JCO.2005.04.9544","article-title":". Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.","volume":"24","author":"Smalley","year":"2006","journal-title":"J Clin Oncol"},{"key":"R29-5-20210128","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1002\/cncr.24552","article-title":". Accelerated treatment using intensity-modulate radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma.","volume":"115","author":"McIntosh","year":"2009","journal-title":"Cancer"},{"key":"R30-5-20210128","first-page":"219","article-title":". Multimodality treatment with helical tomotherapy intensity modulated radiotherapy, capecitabine and photodynamic therapy is feasible and well tolerated in patients with hilar cholangiocarcinoma.","volume":"2","author":"Baisden","year":"2008","journal-title":"Gastrointestinal Cancer Res"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0b013e31827ecd1d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:09:31Z","timestamp":1620950971000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201412000-00005"}},"subtitle":["A Phase II Study"],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e31827ecd1d","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}